Pages that link to "Q30357431"

The following pages link to The future role of gut hormones in the treatment of obesity (Q30357431):

Displaying 34 items.

• Organoid Models of Human Gastrointestinal Development and Disease (Q26771646) (← links)
• The New Era of Drug Therapy for Obesity: The Evidence and the Expectations (Q26827555) (← links)
• Relationship between gut hormones and glucose homeostasis after bariatric surgery (Q27022123) (← links)
• Effects of different metabolic states and surgical models on glucose metabolism and secretion of ileal L-cell peptides: protocol for a cross-sectional study. (Q30385657) (← links)
• Marine Peptides as Potential Agents for the Management of Type 2 Diabetes Mellitus-A Prospect (Q33612142) (← links)
• Homeostasis in anorexia nervosa (Q34009868) (← links)
• Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion? (Q34589770) (← links)
• Gastrointestinal symptoms in morbid obesity (Q34930170) (← links)
• Discovery of Small-Molecule Modulators of the Human Y4 Receptor (Q36050350) (← links)
• Non-alcoholic fatty liver disease and diabetes (Q37091659) (← links)
• G protein-coupled receptors in energy homeostasis (Q38223619) (← links)
• Latest approaches for the treatment of obesity. (Q38475978) (← links)
• The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? (Q38527885) (← links)
• Horizons in the Pharmacotherapy of Obesity (Q38582461) (← links)
• The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond (Q38820260) (← links)
• Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. (Q38820528) (← links)
• Emerging drugs for the treatment of obesity. (Q39031756) (← links)
• GLP-1/glucagon receptor co-agonism for treatment of obesity. (Q39451553) (← links)
• Role of Peptide YY in blood vessel function and atherosclerosis in a rabbit model (Q41100161) (← links)
• Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake (Q41674388) (← links)
• Could hop-derived bitter compounds improve glucose homeostasis by stimulating the secretion of GLP-1? (Q46307017) (← links)
• Characterization and quantification of oxyntomodulin in human and rat plasma using high-resolution accurate mass LC-MS. (Q46531147) (← links)
• Gut hormone polyagonists for the treatment of type 2 diabetes (Q49218095) (← links)
• Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. (Q52674726) (← links)
• Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors. (Q52680710) (← links)
• The Noncaloric Sweetener Rebaudioside A Stimulates Glucagon-Like Peptide 1 Release and Increases Enteroendocrine Cell Numbers in 2-Dimensional Mouse Organoids Derived from Different Locations of the Intestine. (Q52839655) (← links)
• Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats. (Q52954771) (← links)
• A Short-Length Peptide YY Analogue with Anorectic Effect in Mice. (Q55656124) (← links)
• Health effects of resistant starch (Q55919832) (← links)
• Drug-induced diabetes type 2: In silico study involving class B GPCRs (Q61815750) (← links)
• Dietary Polysaccharides in the Amelioration of Gut Microbiome Dysbiosis and Metabolic Diseases. (Q64930147) (← links)
• Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes (Q89113530) (← links)
• The Potential Role of Gut Peptide Hormones in Autism Spectrum Disorder (Q91972772) (← links)
• A novel peptide RIFV suppresses human adipocyte differentiation through the inhibition of C/EBP-β expression (Q92340573) (← links)